
ĀLTIKA

BIOTECH

Company profile

Powering the clean edge.
Australian biotechnology research
with industrial purpose.

Owned by Howe Invest Pty Ltd



PUBLIC OVERVIEW / NOVEMBER 2026

Biology, with industrial purpose.

Āltika Biotech is a biotechnology research platform owned by Howe Invest Pty Ltd, based in Bibra Lake, Western Australia. It brings peptide and enzyme design to advanced materials research, with BSSF as its flagship programme.

01 / BSSF RESEARCH

Rethinking material formation

BSSF investigates a designed peptide to guide solid-state electrolyte formation near ambient conditions. The objective is to reduce dependence on conventional high-temperature sintering. Functional performance and process benefits remain experimental questions.

02 / PHYSICAL PROGRESS

A physically synthesised peptide

Company materials report synthesis by Australian supplier Auspep, with 94% supplier-reported purity against a 90% specification. This is a peptide milestone; it does not establish electrolyte conductivity, stability, cell performance or manufacturing scale.

03 / INDEPENDENT RESEARCH PATHWAY

The 29 October 2026 summit materials report an active Edith Cowan University Research Collaboration Agreement and approved risk assessment. Dr Muhammad Rizwan Azhar and the ECU team lead the physical validation pathway: references and controls, followed by peptide-assisted material testing and characterisation. No completed independent performance result is represented here.

Research status: 29 October 2026. Āltika is a platform brand, not a separately represented incorporated operating company. Conceptual molecular artwork is not experimental imagery.

ĀLTIKA

DEVELOPMENT & COMMERCIAL PATHWAY

ILLUSTRATIVE MANUFACTURER SCENARIO

A$2.19 billion

Potential annual manufacturer value per 100 GWh factory.
A company model, not measured savings, a forecast or Āltika revenue.

REFERENCE OXIDE PROCESS	BSSF PROCESS TARGET	MODELLED DIFFERENCE
A$31.90/kWh	**A$10.00/kWh**	**A$21.90/kWh**

Calculation: A$21.90 × 100,000,000 kWh = A$2.19 billion annually. Assumes successful validation and equivalent usable output. Yield, throughput, equipment, qualification, supply terms and adoption can change the outcome. Financing, tax, integration and timing effects are excluded. This is potential manufacturer value, not Howe Invest revenue.

A STAGED ROUTE TO INDUSTRY

Validate. Evaluate. Qualify. Integrate.

The proposed route progresses from independent material evidence to manufacturer evaluation, qualification and pilot integration, then potential supply or licensing. Priority applications include mining and remote power, data centres and grid storage. These are prospective markets, not validated applications or contracted customers.

LEADERSHIP & OWNERSHIP

Paul Howe - Founder & CEO
Invention and commercial direction.

Kelly Howe - Director
Governance and operations.

Gene Davey - Alternative assets and
Trans-Tasman commercial expansion.

WIDER RESEARCH PLATFORM

LAS-ProFold and the Virtual Materials Lab support computational investigation. Aroha PET Ultra explores enzyme-based PET depolymerisation; Carbo-Lith X1 explores carbon capture and mineralisation. These are enabling or exploratory programmes, without established industrial performance.

Research. Manufacturing. Strategic capital.

admin@howeinvest.com | Bibra Lake, Western Australia

Sources: Howe Invest WA Battery Summit (29 October 2026), October 2026 corporate profile and historical Howetika Clean Edge pitch materials. Company-supplied evidence; underlying certificates and agreements have not been independently authenticated for this overview. Confidential formulations, protocols and research data are excluded.